Key result
Zfpm1 knockdown impairs endocardial differentiation, reduces EndoMT, and disrupts cardiac contractility in vitro.
Why the study?
Because Nfatc1 uniquely labels endocardial cells but is not sufficient for their specification, the regulators that specify endocardial fate remain incompletely defined.
Does Zfpm1 knockdown impair endocardial cell differentiation and endothelial-mesenchymal transition in an in vitro embryonic stem cell differentiation model?
Does Zfpm1 knockdown impair endocardial cell differentiation and endothelial-mesenchymal transition in an in vitro embryonic stem cell differentiation model?
Zfpm1 knockdown impairs endocardial cell differentiation and endothelial-mesenchymal transition in vitro, providing mechanistic insight into cardiac development and non-syndromic tetralogy of Fallot.
Answers are grounded in this paper and cite their sources.
Does not support immediate changes in congenital heart defect management; extends ZFPM1 mutation data to endocardial differentiation mechanisms.
The endocardium is the endothelial component of the heart that forms valves. Endocardial (EC) cells undergo endothelial-mesenchymal transition (EndoMT) which distinguishes them from endothelial (ET) cells, despite sharing markers and a mesodermal origin. Nfatc1, uniquely labels EC cells but is not sufficient for EC cell specification, since knockouts form valves, albeit underdeveloped, therefore the regulators that specify EC fate remain incompletely defined. Using an in vivo Nfatc1 reporter system, we show that EC and ET cells are transcriptionally distinct and identify the transcription factor Zfpm1 (Fog1), as a potential regulator of EC cell specification. In an in vitro embryonic stem cell differentiation model, Zfpm1 knockdown results in an impaired EC cell differentiation, with reduced endothelial-mesenchymal transition and altered contractility and beating phenotype, consistent with reduced differentiation of EC cells affecting the crosstalk with myocardial cells. These findings are consistent with data linking mutations in the human ZFPM1 gene with non-syndromic tetralogy of Fallot. This and the broad expression pattern across all regions of the cardiac outflow tract support a role for Zfpm1 in mammalian EC cell differentiation and endothelial-mesenchymal transition. This study extends the in vivo evidence of its relevance to cardiac development and provides new insights into the transcriptional control of EC lineages.
No takes yet. Share an insight, caveat, or question.
Lohiya et al. (2026) studied Endocardial cell differentiation and endothelial-mesenchymal transition (related to non-syndromic tetralogy of Fallot). Zfpm1 (Fog1) knockdown was evaluated on Endocardial cell differentiation, endothelial-mesenchymal transition, and contractility/beating phenotype. Zfpm1 knockdown in an in vitro embryonic stem cell model impaired endocardial cell differentiation, reduced endothelial-mesenchymal transition, and altered cardiac contractility.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: